The TRAVERSE study tested ALLO316, an allogeneic Transcription Activator-Like Effector Nuclease (TALEN) gene-edited anti-CD70 CAR-T product, in 17 patients with previously treated advanced or metastatic ccRCC [96]. This evidence concerns the gene CD70 and nonpapillary renal cell carcinoma.